AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: CMPS
Report Date: 2026-04-20
Full Report: https://amaly.io/stock/CMPS

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Compass Pathways plc (CMPS) is a clinical-stage biopharmaceutical company developing psychedelic-assisted therapies for mental health disorders. The analysis reveals non-compliance primarily due to a high liquidity ratio exceeding Shariah thresholds across major standards, despite low debt and no non-permissible income. Business activities are generally permissible, but the pre-revenue stage and high cash holdings pose challenges. No inclusion in major Shariah indices confirms the non-compliant status. Investors should monitor for improvements in asset utilization and consult scholars on psychedelic therapies.

Primary Compliance Concerns:
- High liquidity ratio (62.02%) exceeds 30-33% thresholds across AAOIFI, MSCI, and S&P standards
- Insufficient data on interest and non-permissible income, though estimated at 0%
- Potential gharar concerns in psychedelic R&D business model

Purification Requirement: 0.00%
Index Inclusion: Not included in any major Shariah-compliant indices (S&P, MSCI, FTSE, DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 7.6%
Liquidity Ratio: 62.0%
Interest Income Ratio: 0.0%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-09-30

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-17T12:00:00Z

---
Full interactive report: https://amaly.io/stock/CMPS
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.